An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
2022 · Cancer Chemotherapy and Pharmacology · 15 citations
https://doi.org/10.1007/s00280-022-04403-9
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
36
Papers
180
Citations
9
h-index
8
i10-index
Mingyi Kang is an academic researcher from Obstetrics and Gynecology Hospital of Fudan University. The author has contributed to research in topics: Molecular Sensors and Ion Detection & Analytical Chemistry and Sensors & Electrochemical Analysis and Applications. The author has an h-index of 9, co-authored 31 publications.
ORCID: 0000-0003-3469-1754https://doi.org/10.1007/s00280-022-04403-9
https://doi.org/10.1007/s13577-023-00966-8
Click to start Chat